The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy “Test-and-Offer” Era | Zendy

Jeffrey W. Eaton | Zendy; Cheryl Johnson | Zendy; Simon Gregson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy “Test-and-Offer” Era

Author(s) -

Jeffrey W. Eaton,

Cheryl Johnson,

Simon Gregson

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix341

Subject(s) - medicine , antiretroviral therapy , human immunodeficiency virus (hiv) , test (biology) , antiretroviral treatment , sida , diagnostic test , intensive care medicine , pediatrics , virology , viral disease , viral load , paleontology , biology

We compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART) initiation to the costs of ART provision to misdiagnosed HIV-negative persons. Savings from averted unnecessary ART costs were greater than retesting costs within 1 year using assumptions representative of HIV testing performance in programmatic settings. Countries should implement re-testing before ART initiation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research